Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy
Authors:
- 6 January 2016
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (5) , 1194-1196
Abstract
A 46-year-old man was admitted to our hospital in October 2009, following the appearance in June, 4 months earlier, of a skin ulceration on the lower-left side of the chin (Figure 1A) . He had had ...Keywords
This publication has 9 references indexed in Scilit:
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- Anaplastic large cell lymphoma, ALK-positiveCritical Reviews in Oncology/Hematology, 2012
- Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantationAnnals of Hematology, 2012
- Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomasCancer Chemotherapy and Pharmacology, 2012
- Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine TrialJournal of Clinical Oncology, 2010
- Metronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology, 2010
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1993